H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 35.1 DKK 0.57% Market Closed
Market Cap: 35B DKK

H Lundbeck A/S
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

H Lundbeck A/S
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
H Lundbeck A/S
CSE:HLUN A
Stock-Based Compensation
kr37m
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Stock-Based Compensation
kr2.6B
CAGR 3-Years
29%
CAGR 5-Years
35%
CAGR 10-Years
29%
ALK-Abello A/S
CSE:ALK B
Stock-Based Compensation
kr52m
CAGR 3-Years
12%
CAGR 5-Years
5%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
34.8B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
58.45 DKK
Undervaluation 40%
Intrinsic Value
Price

See Also

What is H Lundbeck A/S's Stock-Based Compensation?
Stock-Based Compensation
37m DKK

Based on the financial report for Dec 31, 2024, H Lundbeck A/S's Stock-Based Compensation amounts to 37m DKK.

What is H Lundbeck A/S's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
-3%

Over the last year, the Stock-Based Compensation growth was -10%. The average annual Stock-Based Compensation growth rates for H Lundbeck A/S have been -3% over the past three years .

Back to Top